Congress Overhauling US Patent Laws - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Congress Overhauling US Patent Laws

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

The US patent laws are undergoing their first large revision since the Patent Act of 1952. The America Invents Act, introduced by Senator Leahy (D-VT) on Jan. 25, 2011, was overwhelmingly passed by the US Senate on Mar. 8, 2011. It was then introduced in House of Representatives on Mar. 30, 2011, where it is still awaiting a vote.

The act would introduce reforms that bring US patent laws more in line with those of the EU. In particular, it would revise policy so that patents would be granted on a first-to-file basis, rather than on a first-to-invent basis. Under the current system, a division of the US Patent and Trademark Office settles disputes about who was the first to invent a product, in an expensive and uncertain process that puts cash-strapped academics at a disadvantage.

The first-to-file system is a less ambiguous measure of who has first claim to an invention. This system carries risk to academics, particularly if they begin the process of commercialization before filing. However, the act contains provisions intended to protect inventors, such as the ability to request a postgrant review during the first nine months after issue, and a provision allowing third parties to submit prior art during patent examination. First-to-file status is intended to remove much of the ambiguity around patent filings, and enable a more streamlined, less expensive patent-application process than the current procedure.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here